PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer

Woodford, R; Zhou, D; Lord, SJ; Marschner, I; Cooper, WA; Lewis, CR; John, T; Yang, JCH; Lee, CK

Author(s): Woodford, R; Zhou, D; Lord, SJ; Marschner, I; Cooper, WA; Lewis, CR; John, T; Yang, JCH; Lee, CK;
Details: Publication Year 2022-05,Volume 18,Issue #14,Page 1793-1799
Journal Title: Future Oncology
Publication Type: Review
Abstract: Background: In metastatic non-small-cell lung cancer (mNSCLC), PD-L1 expression is associated with benefit from immune checkpoint inhibitor (ICI) therapy. However, the significance of PD-L1 expression in chemotherapy-treated patients is uncertain. Methods: Using the chemotherapy control arm of first-line randomized trials, a meta-analysis of the association between efficacy outcomes and PD-L1 status was performed, stratified by assay due to inter-assay differences. Results: Across 12 trials and 4378 patients, overall survival (OS) was superior in high PD-L1 versus negative tumors and low versus negative according to 22C3/28-8 assays. When classified by SP142 assay, no significant difference in response or survival was seen between PD-L1 groups. Conclusion: In mNSCLC, high PD-L1-expressing tumors are associated with longer OS and improved objective rate when treated with chemotherapy. Inter-assay variability impacts outcome results.; Biomarkers are naturally occurring cancer traits that can predict certain events. PD-L1 expression is a biomarker used in advanced lung cancer to predict benefit from immunotherapy. However, the association between PD-L1expression and chemotherapy is unclear. The authors analyzed data from 14 large clinical trials and found that PD-L1 expression could also be used to define a type of lung cancer that responds better to chemotherapy.; eng
Keywords: Antineoplastic Combined Chemotherapy Protocols/adverse effects; B7-H1 Antigen/metabolism; *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics; Humans; *Lung Neoplasms/drug therapy/genetics; Prognosis; Pd-l1; biomarkers; chemotherapy; metastatic cancer; non-small-cell lung cancer; prognostic markers
Department(s): Medical Oncology
PubMed ID: 35156837
Publisher's Version: https://doi.org/10.2217/fon-2021-1184
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-05-16 01:15:02

Last Modified: 2025-05-16 01:16:07